Date: 2011-12-19
Type of information: Fundraising
Company: Atox Bio (Israel)
Investors: Esperante Ventures (UK)
Amount: $3.25 million (€2.5 million)
Funding type: financing round
Planned used: With this investment, Atox Bio plans to advance AB103’s Phase 2 study and further expand into new therapeutic categories.
Others: Atox Bio, has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).
AB103 is a rationally designed short peptide acting as a CD28 modulator regulating the host’s inflammatory response. AB103 is undergoing a phase 2 study at 7 leading surgical trauma centers in the US, evaluating its clinical benefit in patients with NSTI. Results of this study are expected by the end of 2012. In October 2011, the FDA has granted AB103 an orphan drug designation.
Therapeutic area: Inflammatory diseases
